CareDx Raises 2026 Revenue Guidance Amid Expansion into Oncology and Cell Therapy
CareDx (CDNA) has raised its revenue outlook for 2026 to a range of $520 million to $530 million. This upward revision follows a strong third quarter characterized by solid operational execution and continued leadership in the transplantation market. The company is actively diversifying its portfolio, moving into specialty oncology and preparing for an entry into the cell therapy sector. A key driver for future growth includes the planned launch of AlloHeme, which is currently slated for the first quarter of 2027.
Tickers: $CDNA
Topics: cell therapy earnings call oncology transplantation
Read the full article at Seeking Alpha
Part of the story Pfizer Raises 2026 Revenue Guidance Amid Strong Growth in Acquired Products (18 articles)